<SEC-DOCUMENT>0001213900-24-078954.txt : 20240916
<SEC-HEADER>0001213900-24-078954.hdr.sgml : 20240916
<ACCEPTANCE-DATETIME>20240916160102
ACCESSION NUMBER:		0001213900-24-078954
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240916
DATE AS OF CHANGE:		20240916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MASIMO CORP
		CENTRAL INDEX KEY:			0000937556
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				330368882
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1228

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33642
		FILM NUMBER:		241300993

	BUSINESS ADDRESS:	
		STREET 1:		52 DISCOVERY
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
		BUSINESS PHONE:		949-297-7000

	MAIL ADDRESS:	
		STREET 1:		52 DISCOVERY
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ea0214708-defa14a_masimo.htm
<DESCRIPTION>DEFINITIVE ADDITIONAL MATERIALS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a) of
the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Amendment No.&nbsp;&nbsp;&nbsp;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a Party other than the Registrant <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Preliminary Proxy Statement</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Definitive Proxy Statement</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Definitive Additional Materials</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Soliciting Material Pursuant to &sect;240.14a-12</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MASIMO CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Registrant as Specified In Its Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement, if
other than the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Payment of Filing Fee (Check the appropriate box):</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">No fee required.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Fee paid previously with preliminary materials.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Persons who are to respond to the collection of information contained
in this form are not required to respond unless the form displays a currently valid OMB control number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>On September 16, 2024, Joe Kiani, Chief Executive Officer of Masimo
Corporation (&ldquo;Masimo&rdquo; or the &ldquo;Company&rdquo;), participated in a conversation with Caroline Hyde on &ldquo;Bloomberg
Technology&rdquo;. The following is a transcript of the conversation, portions of which may be deemed proxy soliciting materials. While
effort has been made to provide an accurate transcription, there may be typographical mistakes, inaudible statements, errors, omissions
or inaccuracies in the transcript.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Caroline Hyde: </B>Coming out of the weekend, it really was the
health side of the equation that stole the show. But as Apple, of course, sinks this morning following last week&rsquo;s product launch
event, the company still hasn&rsquo;t resolved their legal fight with Masimo Corp. There&rsquo;s a blood oxygen detection, of course,
that that company offers, which prompted a US ban on Apple Watches featuring the technology. Now, Masimo has partnered with Google and
Qualcomm to develop a reference platform to help bring more smartwatches to market with their biosensing capabilities. Joining us now
is Joe Kiani, the CEO of the Company. And what is this about? You have impressive health features, but Apple Watch, we just heard the
new unveiling. They&rsquo;re getting sleep apnea and the like. How do you compete there, Joe?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Joe Kiani: </B>Well, we compete based on good science. We have continuous
accurate SpO2, pulse rate. We can even measure hydration, pulse rate variability, and nobody else has that. In fact, I don&rsquo;t understand
how you can do sleep apnea without SpO2. I know clinically it&rsquo;s not done. So it will be interesting to see if Apple&rsquo;s promising
things they can&rsquo;t deliver again, like they did with their SpO2, or if they really have figured out how to do it without SpO2. Time
will tell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Caroline Hyde: </B>So you&rsquo;re offering this platform with Qualcomm.
You&rsquo;re helping Google offer more smartwatches, more health features. It feels as though that, Joe, look, if you don&rsquo;t think
that Apple can deliver what it promises, does that mean more court action? Where does your fight currently stand with Apple and its smartwatch?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Joe Kiani: </B>Well, we, as you know, enjoined Apple from selling
SpO2 in the US. There&rsquo;s a trade secret case that&rsquo;s going to be reheard, and if we win that, then we&rsquo;ll have a broad
injunction against them on photoplethysmography. So they can&rsquo;t even do pulse rate and arrhythmia detection. And then if we win our
patent case, which is about how you do photoplethysmography with very low battery consumption, then that will be an even wider injunction.
So potentially our injunction could go worldwide and much broader. However, what&rsquo;s really cool is this partnership with Google,
which I&rsquo;d love to tell you more about. We&rsquo;re excited about it. Every Android user now can have a real, scientifically based,
continuous, accurate wearable with this reference design we&rsquo;re creating with them. And I think in the next couple of years, you&rsquo;re
going to see a slow--slew of products, from luxury products to smart watches from the typical Android world that will be an incredible
offering for our mutual customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Caroline Hyde: </B>I hate to say it, Joe, because we&rsquo;ve only
got a minute, so I ask for it to be brief, but you&rsquo;ve got some fascinating things happening. You&rsquo;ve got a proxy battle going
on at the moment. They want to see more governance, want to have more board oversight. How do you fight Politan?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Joe Kiani: </B>Well, you saw that Politan was found to have lied
to our shareholders. The court--a federal judge found multiple lies, held them in contempt. So you&rsquo;ve got someone who has no integrity
that talks about governance. Yet you have us, who&rsquo;ve done everything right--morally right, not just even legally. And we&rsquo;ve
made all this progress from bringing the business through COVID and now this incredible Google partnership. I think this should be 91%
to 9%. Only person voting for him should be him.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Caroline Hyde: </B>Joe, we wish we could have more information from
you. Maybe we&rsquo;ll get you back after the vote come September 19. We thank you, Joe Kiani, CEO of Masimo. This is Bloomberg Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This communication includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, in connection
with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding
the 2024 Annual Meeting of Stockholders (the &ldquo;2024 Annual Meeting&rdquo;) of Masimo Corporation (&ldquo;Masimo&rdquo; or the &ldquo;Company&rdquo;)
and the potential stockholder approval of the Board&rsquo;s nominees, Masimo&rsquo;s litigation against Politan Capital Management LP
(&ldquo;Politan&rdquo;) and its affiliates (the &ldquo;Politan Litigation&rdquo;), Masimo&rsquo;s litigation against Apple and the scope
of any injunction related thereto (and together with the Politan Litigation, the &ldquo;Litigation&rdquo;) and access by Android users
to a wearable with Masimo&rsquo;s monitoring technology through Masimo&rsquo;s reference design. These forward-looking statements are
based on current expectations about future events affecting Masimo and are subject to risks and uncertainties, all of which are difficult
to predict and many of which are beyond Masimo&rsquo;s control and could cause its actual results to differ materially and adversely from
those expressed in its forward-looking statements as a result of various risk factors, including, but not limited to (i) uncertainties
regarding the Litigation, (ii) future actions that may be taken by Politan in furtherance of its nomination of director candidates for
election at the 2024 Annual Meeting, (iii) the potential cost and management distraction attendant to Politan&rsquo;s nomination of director
nominees at the 2024 Annual Meeting or to the Politan Litigation and (iv) factors discussed in the &ldquo;Risk Factors&rdquo; section
of Masimo&rsquo;s most recent periodic reports filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;), which may be obtained
for free at the SEC&rsquo;s website at&nbsp;<I><U STYLE="text-decoration: none">www.sec.gov</U></I>. Although Masimo believes that the expectations reflected in its
forward-looking statements are reasonable, the Company does not know whether its expectations will prove correct. All forward-looking
statements included in this communication are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned
not to place undue reliance on these forward-looking statements, which speak only as of today&rsquo;s date. Masimo does not undertake
any obligation to update, amend or clarify these statements or the &ldquo;Risk Factors&rdquo; contained in the Company&rsquo;s most recent
reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable
securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Information Regarding the 2024 Annual Meeting of Stockholders
and Where to Find It</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 15, 2024, the Company filed a revised version of its 2024
proxy statement (the &ldquo;Revised Proxy Statement&rdquo;) and has mailed the Revised Proxy Statement to its stockholders of record as
of the new August 12, 2024 record date for the 2024 Annual Meeting. Any votes submitted by Masimo stockholders in connection with the
2024 Annual Meeting on the prior to the filing of the Revised Proxy Statement will not be counted and previous proxies submitted will
be disregarded, and therefore, all stockholders will need to resubmit their votes, even if they have previously voted. The Company filed
a revised version of the Revised Proxy Statement with the SEC on August 22, 2024, which amended, superseded and replaced in its entirety
the Revised Proxy Statement (the &ldquo;Amended Revised Proxy Statement&rdquo;). THE COMPANY&rsquo;S STOCKHOLDERS ARE STRONGLY ENCOURAGED
TO READ THE AMENDED REVISED PROXY STATEMENT (AND ANY AMENDMENTS AND SUPPLEMENTS THERETO) AND ACCOMPANYING UPDATED GOLD PROXY CARD AS THEY
CONTAIN IMPORTANT INFORMATION. Stockholders may obtain the Amended Revised Proxy Statement and any amendments or supplements thereto and
other documents as and when filed by the Company with the SEC without charge from the SEC&rsquo;s website at&nbsp;www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain Information Regarding Participants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company, its directors and certain of its executive officers
and employees may be deemed to be participants in connection with the solicitation of proxies from the Company&rsquo;s stockholders
in connection with the matters to be considered at the 2024 Annual Meeting. Information regarding the direct and indirect interests,
by security holdings or otherwise, of the Company&rsquo;s directors and executive officers in the Company is included in the Amended
Revised Proxy Statement, which can be&nbsp;found&nbsp;through&nbsp;the&nbsp;SEC&rsquo;s&nbsp;website&nbsp;at&nbsp;https://www.sec.gov/ix?doc=/Archives/edgar/data/937556/000121390024071554/ea0206756-07.htm,
and any changes thereto may be found in any amendments or supplements to the Amended Revised Proxy Statement and other documents as
and when filed by the Company with the SEC, which can be found through the SEC&rsquo;s website at&nbsp;www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">3</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] '0# 2(  A$! Q$!_\0
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M>'Y;]E5[ACY=M$3]^0]/P'4_2OGZYUK6-5O3>7NHW+SDYRLA0+] .!^%=/\
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M[$.OY]/QKZ$\5*%\%ZV , :?/@?]LS6?X(\&:?X1TPQ6Q,US-@SW+C#/Z#V
M]*TO%H_XH[7/^P?/_P"BS6E./*C@S+&/%5;K9;'-ZC8_VC\"GML EM 5QGU$
M(8?J*H^'[/[#^SMY."-VASR\_P#32-W_ /9JZSPW"MS\/](@8D+)I<*DCWB
MJKK=G'I_PIU&SBXCM]%DB3 QPL) _E6AYAXS\.U$_P '9;%PICO?$UK;-N&>
M#) 3QWZ5T_QWT33],\':?J.G:=:VTUOJ,9+0PJG!5NN!ZA:Y?X7-_P 45H2$
M9#>,H_TM\_TKTCXZ0"7X5W[$D&*:%QCN=X']: /0[>5;BVBF4@B1 P(Z'(KY
MH@AC_P"%<?%.]@(^RS:I$D6!Q@7&>/P<5;^(?B3Q)I.B^%[G3M<N;6UU71[<
M/:Q<*AV<D'WSVQTKI]>\,VOA;]G&^L;=S*TR0W,LK+@N[31GI[# _"@#6/\
MR#?A-_OQ?^DIK#\':;]F\?\ Q1E ^6-)%R_7]YO?\N/Y5N'_ )!OPF_WXO\
MTE-:EGIT=OKWQ&N0VY[A8MV1T MNGZT >>Z1I#:S^R[<0QJ3+!)+<H!_TSER
M?TS787OB>+_AG?\ M4.BF721:C'_ #U(\HC\\U/\#8TD^$UDDBAD::<%3T(W
MFN$D\ ;OB2O@#^V;K_A&@3J@L]O3)_U><^G&?TSS0!Z=\)-)?2OAAHD,@99)
?8C<,/^NC%A^A%%=FEND<:1QJ$C10JJ!P .U% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
